US Patent 7,842,282: Scope, Claims, Expiration and Sclerotherapy Patent Landscape

US Patent 7,842,282 protects methods of treating blood vessels with a sclerosing-agent microfoam generated from a pressurized, multi-component dispensing device. Its core coverage is directed to the combination of a sclerosant solution, an inert-gas environment, a blood-dispersible pressurized gas, and a foaming pathway or connector system that produces a stable microfoam. The patent is narrower than a general claim to sclerotherapy or polidocanol foam because infringement requires practice of the claimed method with a device having the specified structural features.

The most commercially relevant product associated with this technology is polidocanol injectable foam, marketed in the United States as Varithena by BTG, now part of Boston Scientific. The patent should be assessed as a device-and-method patent rather than as a broad composition patent.

What does US Patent 7,842,282 cover?

The patent covers two independent method claims.

Claim 1 requires:

A patient in need of sclerotherapy of a blood vessel.
Administration of a microfoam.
A housing containing a pressurizable chamber.
A solution containing at least one sclerosing agent in a physiologically acceptable solvent.
A pathway and outlet orifice for dispensing the solution.
A mechanism capable of opening and closing the pathway.
An inlet for a pressurized, physiologically acceptable gas dispersible in blood.
Contact between the gas and sclerosant solution to create a gas-solution mixture.
At least one foaming element in the outlet pathway.
Storage of the gas in a container engaging the housing.
Storage of the sclerosant solution in the presence of at least one inert gas.

Claim 17 is a second independent method claim. It recites a similar treatment method but expressly requires a pressurized container containing a physiologically acceptable blood-dispersible gas. Unlike claim 1, claim 17 does not expressly require the gas container to have the detailed engaging means recited in claim 1.

The independent claims therefore combine treatment, formulation storage, pressurized gas handling and foam-generation hardware. A device that merely contains polidocanol, or that produces foam through a different mechanism, would not necessarily fall within the claims.

How strong is the independent claim scope?

The claims have meaningful technical specificity but limited breadth.

Claim element	Scope effect
“Method of treating”	Requires actual administration to a patient or blood vessel, not merely manufacture or sale of a device
“Microfoam”	Requires a foam product rather than a liquid sclerosant
Sclerosing-agent solution	Limits the method to sclerosant-containing formulations
Blood-dispersible gas	Excludes gases that do not satisfy the claimed physiological and blood-dispersibility requirement
Inert gas in the solution storage environment	Adds a storage and packaging limitation
Pressurizable chamber	Requires a pressurized or pressurizable delivery architecture
Foaming element	Requires a defined mechanism for producing the foam
Engaging gas container	Claim 1 requires an interaction between the gas container and solution housing
“Comprising”	Permits additional components, gases, valves and structural elements

The use of “comprising” makes the claims open-ended. A competing device may include additional valves, chambers, sensors or mixing components and still satisfy the claim if every required element is present.

The main vulnerability is element-by-element proof. The patent does not claim every microfoam sclerotherapy treatment. It claims a particular delivery architecture used in the treatment.

What do dependent claims 2 through 16 protect?

The dependent claims focus on foam performance and mechanical details.

Foam dimensions and stability

Claim 2 requires a foaming passage with a cross-sectional dimension of 0.1 to 30 micrometers. The resulting microfoam must have:

Density of 0.07 to 0.19 g/ml; and
Half-life of at least two minutes.

Claim 19 repeats these limitations for claim 17.

These numerical limitations create a potentially strong infringement screen if a competing product’s device and foam specifications are documented. They also create design-around opportunities. A product that produces a foam outside the density range, uses a different foam-generation route, or lacks the specified passage may avoid literal infringement, subject to equivalents analysis.

Gas-container removal and pressure control

Claims 3 and 16 cover removal of the pressurized gas source before release of the gas-solution mixture, after the mixture has been pressurized to a predetermined level. This limitation appears directed to a preparation sequence in which the gas source is disconnected or removed before administration.

Claim 4 further requires that the gas inlet include the outlet orifice used to dispense the gas-solution mixture.

These claims may be difficult to apply to systems that maintain a permanently connected gas source or use a premanufactured foam canister.

Connector and engagement architecture

Claims 5 through 15 protect specific mechanical arrangements, including:

An intermediate engaging element;
A removable part of the intermediate element;
A foaming element within the intermediate element;
A connector joining the solution housing and gas container;
A substantially cylindrical connector with open ends;
A cam track that moves the containers together as they rotate;
A release track for separating the containers;
Detents that indicate the progress of gas introduction;
An aerosol valve actuator mechanism;
A removable spacer or annular collar.

These claims are narrower than the independent claims but are commercially important because they target the physical configuration of a disposable or user-activated foam-generation kit.

What is the likely claim construction?

Several terms are central to claim interpretation.

“Microfoam”

The claims do not rely only on the word “microfoam.” Claims 2 and 19 provide objective density, stability and passage-size parameters. For those dependent claims, the numerical limitations may be more important than a generalized clinical description of microfoam.

“Physiologically acceptable gas dispersible in blood”

The language is directed to gases capable of dissolving or dispersing in blood without creating an unacceptable embolic burden. Carbon dioxide is the most obvious candidate because of its high blood solubility. Oxygen and certain gas mixtures could raise separate technical and construction questions.

The claim language does not identify a single gas by name. A competitor cannot assume that changing the gas avoids the patent if the substitute still meets the functional limitation.

“Stored in the presence of at least one inert gas”

This limitation concerns the storage environment of the sclerosant solution. It may cover a solution stored under an inert-gas headspace or in a container in which the solution is exposed to an inert gas. It is materially different from a claim requiring inert gas to be present in the final administered foam.

“Foaming element”

The term is broad in the independent claims but becomes more specific in the dependent claims. It can potentially encompass a porous element, mesh, passage, filter or mixing structure that promotes gas-liquid interaction. Claims 2 and 19 narrow the relevant structure to a passage within a specified dimensional range.

“Administering”

Because the claims are method claims, a treatment step is required. This creates potential differences between direct infringement by a physician or healthcare provider and indirect infringement allegations against a manufacturer or distributor. Device sales alone do not automatically establish direct infringement of a treatment method.

When does US Patent 7,842,282 lose exclusivity?

US Patent 7,842,282 was issued on November 30, 2010.[1] Its enforceable term is generally measured from the applicable nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any other statutory modifications. Based on the patent’s prosecution history and priority structure, the ordinary term should be assessed as a 20-year term running from the relevant US or international filing date, rather than from the issue date.

The patent is now beyond its ordinary commercial exclusivity period or is at the end of that period, depending on the controlling filing-date and term-adjustment calculation recorded by the USPTO. A definitive freedom-to-operate opinion should use the USPTO Patent Center term data and any recorded patent-term adjustment rather than rely solely on the issue date.

Event	Date or assessment
US patent number	7,842,282
Issue date	November 30, 2010
Patent type	Method claims directed to sclerotherapy using microfoam
Ordinary term framework	20 years from the relevant nonprovisional or PCT filing date
Patent-term adjustment	Must be checked in USPTO records
Current commercial relevance	Relevant to historical and legacy device configurations; term status must be confirmed against USPTO records

Patent expiration does not eliminate other barriers. Related continuation, divisional or improvement patents may have later expiration dates and may cover the commercial product more directly.

What FDA products are relevant to this patent?

Varithena

Varithena is a polidocanol injectable foam product approved by the FDA for treatment of incompetent veins and visible varicosities of the great saphenous vein system and accessory veins.[2] It is supplied as a foam-generating pharmaceutical product rather than as a conventional liquid sclerosant.

Its relevance to US 7,842,282 arises from the overlap between:

A sclerosing-agent formulation;
A pressurized delivery system;
A blood-dispersible gas;
Foam generation before or during administration; and
Treatment of venous disease by sclerotherapy.

The existence of product overlap does not by itself establish infringement. The commercial device, manufacturing process and product instructions must be compared against each asserted claim.

Asclera

Asclera is polidocanol injection, a liquid sclerosant approved for sclerotherapy of uncomplicated spider veins and uncomplicated reticular veins.[3] It is not the same dosage form as polidocanol injectable foam.

A liquid polidocanol product administered without the claimed gas-mixing and foaming system would generally present a substantially lower risk under the claims of US 7,842,282.

Sotradecol and other liquid sclerosants

Sodium tetradecyl sulfate products and other liquid sclerosants are relevant therapeutic comparators but generally do not implicate this patent unless used with a device and method satisfying the claimed gas, storage and foaming limitations.

What patents protect Varithena and related microfoam products?

The relevant landscape is broader than US 7,842,282. It includes at least five patent categories:

Patent category	Typical protected subject matter	Relevance
Foam composition patents	Sclerosant, solvent, gas, surfactant and concentration ranges	Can remain relevant after device patents expire
Foam-generation patents	Mixing chambers, porous elements, filters and gas-liquid contact	Closest category to US 7,842,282
Container and packaging patents	Dual-container systems, valves, spacers and connectors	Targets commercial delivery kits
Method-of-treatment patents	Venous indications, dosage, administration and ultrasound-guided treatment	Can create method-of-use exposure
Manufacturing patents	Sterile filling, inert-gas storage, pressure control and stability	May block technically equivalent manufacturing processes

Earlier foam-sclerotherapy patents associated with Cabrera and other developers established the clinical and formulation foundation for foam sclerosants.[4] Later patents associated with BTG and its affiliates focused on pharmaceutical-grade polidocanol foam, storage stability, canister design, administration and manufacturing.

A competitor’s freedom to operate therefore cannot be determined from the expiration of US 7,842,282 alone. The key question is whether later patents claim the same product configuration or a protected manufacturing step.

What is the Orange Book status of the relevant products?

FDA Orange Book listings are product-specific. An approved drug may have listed patents covering the active ingredient, formulation, method of use or product delivery system.[5]

For polidocanol foam, the commercially relevant regulatory product is Varithena, approved under NDA 205098.[2] Asclera is a separate polidocanol product approved under a different NDA and dosage form.[3]

US 7,842,282 should be checked against the Orange Book patent listing for the applicable NDA and product presentation. A patent that is absent from the Orange Book may still have enforcement significance, particularly if it concerns a device, manufacturing process or method claim not eligible for listing under FDA rules. Conversely, an Orange Book listing does not establish validity or infringement.

Were Paragraph IV challenges filed against the relevant products?

Paragraph IV litigation risk is concentrated around the approved drug product and patents listed in the Orange Book. A generic applicant may file an ANDA with a Paragraph IV certification alleging that a listed patent is invalid, unenforceable or not infringed.[5]

For a device-intensive foam product, the practical risk is more complex:

A generic product may use a different canister or foam-generation pathway.
A 505(b)(2) applicant may rely partly on the reference product while proposing a different presentation.
Device patents may not be listed or may not provide the same litigation trigger as formulation or method patents.
A method claim may be relevant to induced-infringement litigation even if the ANDA product label omits a patented indication.

No conclusion about a specific Paragraph IV filing should be drawn from the patent number alone. The litigation record must be matched to the NDA, listed patent and asserted claim set.

Which companies are challenging or competing with this technology?

The competitive field includes:

Boston Scientific, through Varithena and related venous-intervention technologies.
Manufacturers of liquid polidocanol, including products competing with Asclera.
Manufacturers of sodium tetradecyl sulfate injections.
Device companies developing physician-mixed foam systems.
Developers of catheter-based or thermal alternatives to foam sclerotherapy.

The principal product-level competitive distinction is between ready-to-use or controlled-generation foam and physician-prepared liquid-to-foam systems. The latter may avoid specific container-engagement claims but can still encounter composition, method-of-use or manufacturing patents.

What generic launch risks exist?

A generic or follow-on applicant would face four separate risks.

Device equivalence

A product that uses the same dual-container, actuator, connector, cam-track or spacer architecture may read on claims 5 through 15. A different mixing chamber or permanently integrated gas source may reduce that risk.

Foam specifications

Meeting the claimed density, half-life and passage dimensions could create exposure under claims 2 and 19. A design-around would need to consider both literal infringement and the doctrine of equivalents.

Label-induced infringement

A label directing administration of a blood-vessel sclerotherapy microfoam may support an induced-infringement theory if the product and instructions satisfy the device limitations.

Later patent families

Even if US 7,842,282 is expired, later patents may cover the commercial product’s formulation, packaging, manufacturing process or approved use. These later rights may present the more material launch barrier.

What patent litigation affects US 7,842,282?

The relevant litigation review should cover:

District-court cases naming patent 7,842,282;
Inter partes review or post-grant proceedings;
Federal Circuit decisions;
Patent-term adjustment records;
Assignment and merger documents;
Terminal disclaimers;
Continuations and divisionals;
Orange Book litigation concerning Varithena.

The claim set supplied does not establish whether any claim was canceled, amended, disclaimed or held invalid after issuance. A litigation conclusion cannot be inferred from the issued patent text.

How strong is the patent estate?

US 7,842,282 is strongest against a system that reproduces the claimed physical workflow:

The sclerosant solution is stored under inert gas.
A separate pressurized blood-dispersible gas container is attached to the solution housing.
The two containers engage through a connector or intermediate element.
Gas and solution mix under pressure.
The mixture passes through a foaming element.
The resulting microfoam is administered for sclerotherapy.

It is weaker against:

Liquid sclerosant administration;
Physician-prepared foam using syringes;
A single prefilled foam canister;
A foam made without the claimed passage structure;
A device in which the gas source is never removed;
A product whose storage environment does not include inert gas;
A treatment method that does not use the claimed device configuration.

The patent is therefore a targeted platform patent. It has higher value for blocking a particular disposable delivery architecture than for controlling the entire microfoam sclerotherapy market.

What licensing and settlement issues should be reviewed?

Commercial diligence should identify:

Assignments from the original applicant to BTG or successor entities;
Exclusive or field-limited licenses covering foam sclerotherapy;
Agreements involving Varithena development or commercialization;
Patent settlements with generic or 505(b)(2) applicants;
Covenants not to sue;
Royalty-bearing improvements;
Geographic restrictions;
Sublicense rights and change-of-control provisions.

A patent assignment is not the same as a license. The USPTO assignment database can establish recorded ownership, but confidential license economics and settlement restrictions may appear only in court filings, SEC disclosures or transaction documents.

What geographic coverage exists?

US 7,842,282 provides rights only in the United States. Comparable protection must be reviewed separately in:

Europe;
The United Kingdom;
Canada;
Australia;
Japan;
China;
Other PCT national-phase jurisdictions.

Foreign counterparts may have different claim scope, prosecution amendments, opposition outcomes and expiration dates. A US design-around may still infringe a foreign counterpart, and a foreign patent expiration date does not control US launch timing.

Key Takeaways

US 7,842,282 is a device-enabled method patent for administering sclerosing-agent microfoam.
Its core limitations are a pressurizable sclerosant chamber, a pressurized blood-dispersible gas source, inert-gas storage, gas-liquid mixing and a foaming element.
Claim 1 adds detailed engagement requirements between the gas container and solution housing.
Claim 17 is structurally broader in some respects because it requires a pressurized gas container but does not recite all of claim 1’s connector limitations.
Claims 2 and 19 impose objective foam-performance and passage-size limitations.
Claims 5 through 15 target connectors, cam tracks, detents, actuator mechanisms and removable spacers.
Liquid polidocanol and sodium tetradecyl sulfate products generally present less risk than products using the claimed microfoam device architecture.
Varithena is the principal FDA-approved commercial product relevant to this technology.
The patent’s ordinary term is governed by the relevant filing date and USPTO patent-term adjustment, not its 2010 issue date.
Expiration of this patent would not eliminate later composition, manufacturing, packaging or method-of-use patents.
A complete launch analysis requires a claim chart against the actual device, formulation, label and manufacturing process.

FAQs

Does US Patent 7,842,282 cover polidocanol itself?

No. The claims require a method of administering microfoam using specified pressurized gas, storage and device components. They do not broadly claim polidocanol as a chemical compound.

Can a physician-mixed foam avoid US 7,842,282?

Potentially. A physician-mixed foam may avoid the patent if it does not use the claimed housing, pressurized gas container, inert-gas storage condition and foaming pathway. Other patents and regulatory requirements may still apply.

Does expiration of US 7,842,282 permit immediate generic launch of Varithena?

No. Launch timing also depends on Orange Book patents, later patent families, regulatory exclusivity, product-specific requirements and any litigation or settlement restrictions.

Are claims 2 and 19 composition claims?

No. They are dependent method claims. Their numerical density, half-life and passage-size limitations apply to the microfoam generated and administered in the claimed treatment method.

Can a permanently integrated canister design avoid the patent?

It may avoid claims requiring a removable or separately engaging gas container, but it could still satisfy broader elements of an independent claim. The result depends on the complete device architecture and claim construction.

References

United States Patent and Trademark Office. (2010). US Patent No. 7,842,282, device and method for producing and administering microfoam.
U.S. Food and Drug Administration. (2013). Varithena (polidocanol injectable foam) prescribing information, NDA 205098.
U.S. Food and Drug Administration. (2010). Asclera (polidocanol injection) prescribing information, NDA 021201.
Cabrera Garrido, J. R., Cabrera Garcia-Olmedo, J. R., & Garcia-Olmedo Dominguez, M. (2001). Foam sclerotherapy and related sclerosant delivery technology. European patent and medical literature records.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0028692.2	Nov 24, 2000

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	356613	⤷ Start Trial
Australia	2002223885	⤷ Start Trial
Australia	2388502	⤷ Start Trial
Canada	2429674	⤷ Start Trial
Germany	60127290	⤷ Start Trial
European Patent Office	1337238	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,842,282